Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07307300

Study on Risk Assessment for Patients With Microscopic Hematuria (Non-Visible Blood in Urine) Using a Urine Marker Test

The goal of this clinical study is to learn how well a urine test called Xpert® Bladder Cancer Detect (Xpert BC-D) can help doctors assess the risk of bladder cancer in people with non-visible blood in their urine (microscopic hematuria). The main questions it aims to answer are:

* Can the Xpert BC-D test accurately identify people at higher risk for bladder cancer? * Can combining the test results with other clinical information improve risk assessment compared to standard evaluation methods?

Participants will:

* Have leftover urine from the routine initial evaluation tested with the Xpert® Bladder Cancer Detect assay * Complete questionnaires about urinary symptoms using the modified IPSS and ICIQ-FLUT-S forms * Attend a first visit for medical evaluation and cystoscopy * Attend a follow-up visit 3 to 6 months later for additional testing and questionnaires

This study includes adults over 40 years of age who have had microscopic hematuria detected within the past six months. People with a history of bladder cancer, urinary tract surgery, or certain other medical conditions, as well as individuals who are currently pregnant, cannot participate.

The study will be conducted at 20-24 sites in Germany and Austria and will last approximately 27 months, with each participant involved for about 6 months. The results of this study may help doctors better decide which patients need further invasive testing, potentially reducing unnecessary procedures.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Hematuria Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Hemorrhage Male Urogenital Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Urination Disorders Urogenital Diseases Urologic Diseases

Age range

40 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Urology and Pediatric Urology University Hospital Ulm

Ulm, 89081, Germany

Location contact

Christian Bolenz, Univ. Prof. Dr. med.

CONTACT

[email protected]

+49 731 500 58000

Christian Bolenz, Univ. Prof. Dr. med.

PRINCIPAL_INVESTIGATOR

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Signed consent form after being informed about the study
  • Willing and able to follow the study requirements
  • Non-visible blood in the urine, found within the past 6 months
  • Age over 40 years

Exclusion criteria

  • Previous diagnosis of bladder cancer
  • Too much protein in the urine (shown by urine test)
  • Current urinary tract infection (symptoms like pain or frequent urination, plus bacteria found in urine test)
  • Current pain in the urinary tract or lower belly, pain score greater than 2 on a 0-10 scale
  • Signs of kidney-related blood in the urine (found by special urine test)
  • Bladder examination with a camera (cystoscopy) within the past 12 months
  • Pregnancy
  • Visible blood in the urine within the past year
  • Previous surgery on the urinary tract
  • Previous radiation treatment to the pelvic area
  • Permanent tube or foreign body in the urinary tract (such as a catheter)
  • Participation in another clinical study at the same time or within 30 days before this study
  • Detained under legal or official authority
  • Medical, psychological, or social problems that would make it hard to follow the study requirements
  • Not able to understand the study information well enough to give consent

Treatment and study plan

Primary outcomes

  1. Validating results of a recent metanalysis (UroDetect II) achieving an overall sensitivity of the Xpert BC-D for UCas of >0.70 and a specificity of >0.65

    Time frame: From enrollment until completion of follow-up at 6 months

Secondary outcomes

  1. Effective detection of high impact tumors (HITs, defined as Ta G3/HG, CIS, and ≥T1 urothelial cancer)

    Time frame: From enrollment until completion of follow-up at 6 months

  2. Validating results from a recent meta-analysis demonstrating improved risk stratification by combining the Xpert BC-D results with clinical parameters

    Time frame: From enrollment until completion of follow-up at 6 months

  3. Simulating application of current major guideline recommendations, a significantly better discrimination between patients at low/high risk for subsequent UCa diagnosis for: The Xpert BC-D results and combinations from Xpert BC-D results and clinical

    Time frame: From enrollment until completion of follow-up at 6 months

  4. Cost-benefit considerations (based on structured information e.g. from GOÄ and EBM)

    Time frame: From enrollment until completion of follow-up at 6 months

  5. Investigating the rate of negative TUR-Bs triggered by standard-of-care (SOC) vs. positive findings by Xpert BC-D results and respective combination with clinical results. (study not powered for confirmation of a significant difference)

    Time frame: From enrollment until completion of follow-up at 6 months

  6. Prospective assessment of symptoms of nvH patients (assessment using modified versions of ICIQ-FLUTS and IPSS)

    Time frame: From enrollment until completion of follow-up at 6 months

  7. Investigating the frequency of conditions requiring medical and/or surgical intervention resulting from nvH assessment

    Time frame: From enrollment until completion of follow-up at 6 months

Study contacts

Contact information is provided by the study sponsor or research team.

Christian Bolenz, Univ. Prof. Dr. med.

CONTACT

[email protected]

+49 731 500 58000

Sponsors and collaborators

Lead sponsor

Christian Bolenz

Other

Collaborators

  • Cepheid
  • Prof. Dr. med. Bernd Schmitz-Dräger

Registry information

Official study title

Risk Stratification of Patients With Non-Visible Hematuria - A Prospective Validation Study Using a Urine Marker-Based Assessment (Xpert® Bladder Cancer Detect)

Acronym: UroDetect III

Important dates

Study start
2026
Primary completion
2028
Study completion
2028
First posted
Dec 29, 2025
Registry last updated
Dec 29, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.